A Stenzl
Overview
Explore the profile of A Stenzl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
1326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryniak C, Frommer S, Junger D, Lohmann S, Stadelmaier M, Schmutz P, et al.
Int J Comput Assist Radiol Surg
. 2022 Nov;
18(3):575-585.
PMID: 36370329
Purpose: Supporting the surgeon during surgery is one of the main goals of intelligent ORs. The OR-Pad project aims to optimize the information flow within the perioperative area. A shared...
2.
Harland N, Amend B, Lipke N, Brucker S, Fend F, Herkommer A, et al.
Urologe A
. 2021 Jul;
60(9):1159-1166.
PMID: 34255127
In the context of cancer surgery, there is always a trade-off between oncological safety and preservation of function. This is especially true in pelvic surgery due to the close relationship...
3.
Lawaczeck L, Fischer A, Norz V, Rausch S, Bedke J, Stenzl A, et al.
Urologe A
. 2021 Jun;
60(9):1184-1187.
PMID: 34100955
We present the case of a 57-year-old man who developed an intraperitoneal bladder fistula with BCG-induced (bacillus Calmette-Guérin) abdominal granulomatosis after transurethral resection of a papillary non-muscle invasive bladder cancer...
4.
Rexer H, Stenzl A, Bogemann M
Aktuelle Urol
. 2021 May;
52(3):218-219.
PMID: 34020501
No abstract available.
5.
Gierth M, Breyer J, Zeman F, Fritsche H, Cordes J, Karl A, et al.
World J Urol
. 2021 May;
39(10):3799-3805.
PMID: 34002265
Purpose: Photodynamic diagnosis and white-light TURB with adjuvant intravesical chemotherapy (ICT) is widely used in treatment of bladder cancer. This non-inferiority trial is designed to demonstrate non-inferiority regarding recurrence-free survival...
6.
Aicher W, Korn M, Reitnauer L, Maurer F, Hennenlotter J, Black P, et al.
BMC Urol
. 2021 Apr;
21(1):60.
PMID: 33845814
Background: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We...
7.
Rassweiler J, Pini G, Liatsikos F, Georgiev M, Roupret M, Breda A, et al.
Urologe A
. 2021 Feb;
60(3):306-317.
PMID: 33559012
The coronavirus has challenged all medical systems worldwide. Herein both waves of COVID-19 (coronavirus disease 2019) in spring and autumn 2020 differ principally. Whereas Europe was hit by the first...
8.
Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, et al.
World J Urol
. 2020 Feb;
38(6):1587-1588.
PMID: 32076820
In multivariate analysis, GS of the regular prostatectomy specimen was the only statistically significant parameter for pT2R1 prostate cancer.
9.
Horwich A, Babjuk M, Bellmunt J, Bruins H, de Reijke T, De Santis M, et al.
Ann Oncol
. 2019 Nov;
30(11):1697-1727.
PMID: 31740927
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary...
10.
Peisen F, Thaiss W, Tietze N, Rausch S, Amend B, Nikolaou K, et al.
Urologe A
. 2019 Nov;
58(12):1451-1460.
PMID: 31705144
Background: Immune checkpoint inhibitors (ICI) have led to great advances in the therapy of metastatic renal cell and urothelial carcinoma. Currently ICI are approved for the first-line therapy of cisplatin-unfit...